التفاصيل البيبلوغرافية
| العنوان: |
Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer. |
| المؤلفون: |
Brennan, Donal J, Brändstedt, Jenny, Rexhepaj, Elton, Foley, Michael, Pontén, Fredrik, Uhlén, Mathias, Gallagher, William M, O'Connor, Darran P, O'Herlihy, Colm, Jirstrom, Karin |
| المساهمون: |
Dept of Obstetrics and Gynaecology, National Maternity Hospital, Holles Street, Dublin 2, Ireland. donal.brennan@ucd.ie |
| سنة النشر: |
2010 |
| المجموعة: |
Lenus - Irish Health Publications Archive (HSE - Health Service Executive) |
| مصطلحات موضوعية: |
Disease-Free Survival, Female, Humans, Hydroxymethylglutaryl CoA Reductases, Immunohistochemistry, Microarray Analysis, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Ovarian Neoplasms, Tumor Markers, Biological |
| الوصف: |
BACKGROUND: Our group previously reported that tumour-specific expression of the rate-limiting enzyme in the mevalonate pathway, 3-hydroxy-3-methylglutharyl-coenzyme A reductase (HMG-CoAR) is associated with more favourable tumour parameters and a good prognosis in breast cancer. In the present study, the prognostic value of HMG-CoAR expression was examined in tumours from a cohort of patients with primary epithelial ovarian cancer. METHODS: HMG-CoAR expression was assessed using immunohistochemistry (IHC) on tissue microarrays (TMA) consisting of 76 ovarian cancer cases, analysed using automated algorithms to develop a quantitative scoring model. Kaplan Meier analysis and Cox proportional hazards modelling were used to estimate the risk of recurrence free survival (RFS). RESULTS: Seventy-two tumours were suitable for analysis. Cytoplasmic HMG-CoAR expression was present in 65% (n = 46) of tumours. No relationship was seen between HMG-CoAR and age, histological subtype, grade, disease stage, estrogen receptor or Ki-67 status. Patients with tumours expressing HMG-CoAR had a significantly prolonged RFS (p = 0.012). Multivariate Cox regression analysis revealed that HMG-CoAR expression was an independent predictor of improved RFS (RR = 0.49, 95% CI (0.25-0.93); p = 0.03) when adjusted for established prognostic factors such as residual disease, tumour stage and grade. CONCLUSION: HMG-CoAR expression is an independent predictor of prolonged RFS in primary ovarian cancer. As HMG-CoAR inhibitors, also known as statins, have demonstrated anti-neoplastic effects in vitro, further studies are required to evaluate HMG-CoAR expression as a surrogate marker of response to statin treatment, especially in conjunction with current chemotherapeutic regimens. |
| نوع الوثيقة: |
other/unknown material |
| اللغة: |
English |
| تدمد: |
1471-2407 |
| العلاقة: |
Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer. 2010, 10:125 BMC Cancer; http://hdl.handle.net/10147/106901Test; BMC cancer |
| DOI: |
10.1186/1471-2407-10-125 |
| الإتاحة: |
https://doi.org/10.1186/1471-2407-10-125Test
http://hdl.handle.net/10147/106901Test |
| رقم الانضمام: |
edsbas.20EEF60 |
| قاعدة البيانات: |
BASE |
Full Text Finder